blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2593565

EP2593565 - METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUNDS THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  31.10.2014
Database last updated on 14.09.2024
Most recent event   Tooltip31.10.2014Application deemed to be withdrawnpublished on 03.12.2014  [2014/49]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[N/P]
Former [2013/21]For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 05843-4000 / US
Inventor(s)01 / SUN, Jin-Hua
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
02 / GAO, Min
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
03 / O'BOYLE II, Donald R.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
04 / LEMM, Julie A.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
05 / ROBERTS, Susan B.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
06 / BELEMA, Makonen
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
07 / MEANWELL, Nicholas A.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford Connecticut 06492 / US
 [2013/21]
Representative(s)Reitstötter Kinzebach
Patentanwälte
Sternwartstraße 4
81679 München / DE
[N/P]
Former [2013/21]Reitstötter - Kinzebach
Patentanwälte Sternwartstrasse 4
81679 München / DE
Application number, filing date11807424.413.07.2011
WO2011US43785
Priority number, dateUS20100364851P16.07.2010         Original published format: US 364851 P
[2013/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012009394
Date:19.01.2012
Language:EN
[2012/03]
Type: A2 Application without search report 
No.:EP2593565
Date:22.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 19.01.2012 takes the place of the publication of the European patent application.
[2013/21]
Search report(s)International search report - published on:US28.02.2013
(Supplementary) European search report - dispatched on:EP05.11.2013
ClassificationIPC:C12Q1/68, C12Q1/70, C12Q1/02, C12Q1/18, G01N33/50
[2013/49]
CPC:
C12Q1/18 (EP,US); C12Q1/025 (US); G01N33/5008 (EP,US);
G01N2333/186 (EP,US)
Former IPC [2013/21]C12Q1/68, C12Q1/70
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/21]
TitleGerman:VERFAHREN ZUR IDENTIFIKATION VON KOMBINATIONEN AUS NSSA-ANZIELENDEN VERBINDUNGEN MIT SYNERGISTISCHER WIRKUNG ZUR HEMMUNG EINER HEPATITIS-C-VIRENREPLIKATION[2013/21]
English:METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUNDS THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION[2013/21]
French:PROCÉDÉS POUR L'IDENTIFICATION DE COMBINAISONS DE COMPOSÉS CIBLANT DE NS5A QUI AGISSENT SYNERGIQUEMENT POUR INHIBER LA RÉPLICATION DU VIRUS DE L'HÉPATITE C[2013/21]
Entry into regional phase16.01.2013National basic fee paid 
16.01.2013Search fee paid 
16.01.2013Designation fee(s) paid 
16.01.2013Examination fee paid 
Examination procedure16.01.2013Examination requested  [2013/21]
03.06.2014Application deemed to be withdrawn, date of legal effect  [2014/49]
09.07.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2014/49]
Fees paidRenewal fee
10.07.2013Renewal fee patent year 03
14.07.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2004014313  (BRISTOL MYERS SQUIBB CO [US], et al) [I] 1-28 * the whole document * * page 113, line 22 - page 117; tables 4-7 * * page 1, lines 5-11 * * page 3, line 12 - page 5, line 10 * * pages 23-31; claims 1-39 *;
 [I]US2006276511  (SERRANO-WU MICHAEL [US], et al) [I] 1-28 * the whole document * * paragraphs [0025] , [0026] , [0222] - [0225] - [0316] - [0326] *;
 [E]WO2011109037  (ENANTA PHARM INC [US], et al) [E] 1-28* the whole document *;
 [I]  - OWENS CHRISTOPHER M ET AL, "A COMBINATION OF A NOVEL CYCLOPHILIN INHIBITOR AND A NOVEL PUTATIVE NS5A INHIBITOR WITH POTENT ANTI-HCV ACTIVITY SYNERGISTICALLY INHIBITS VIRAL REPLICATION AND CURES REPLICON CELLS IN THE PRESENCE OR ABSENCE OF INTERFERON-alpha", HEPATOLOGY, & 60TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES; BOSTON, MA, USA; OCTOBER 30 -NOVEMBER 03, 2009, (20091030), vol. 50, no. 4, Suppl. S, ISSN 0270-9139, page 1046A, XP008165527 [I] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1002/hep.23306
 [Y]  - R. A. FRIDELL ET AL, "Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20100628), vol. 54, no. 9, doi:10.1128/AAC.00556-10, ISSN 0066-4804, pages 3641 - 3650, XP055073884 [Y] 1-28 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.1128/AAC.00556-10
 [Y]  - SARRAZIN G ET AL, "Mutations in de Protein Kinase-Binding Domain of the NS5A protein in Patens Infected woth Hepatitis C. Virus Type 1a Are Associated with Treatment Response", JOURNAL OF INFECTIOUS DISEASES.JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, (20000101), vol. 181, doi:10.1086/315263, ISSN 0022-1899, pages 432 - 441, XP002989689 [Y] 1-28 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.1086/315263
 [Y]  - GAO MIN ET AL, "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE (AND SUPPLEMENTARY INFORMATION), NATURE PUBLISHING GROUP, UNITED KINGDOM, (20100101), vol. 465, no. 7294, doi:10.1038/NATURE08960, ISSN 0028-0836, pages 96 - 100, XP008131386 [Y] 1-28 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.1038/nature08960
 [Y]  - JULIE A LEMM ET AL, "Identification of Hepatitis C Virus NS5A Inhibitors", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 84, no. 1, doi:10.1128/JVI.01360-09, ISSN 0022-538X, (20100101), pages 482 - 491, (20091007), XP002639563 [Y] 1-28 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.1128/JVI.01360-09
 [Y]  - FRANGEUL L ET AL, "MUTATIONS IN NS5A REGION OF HEPATITIS C VIRUS GENOME CORRELATE WITH PRESENCE OF NS5A ANTIBODIES AND RESPONSE TO INTERFERON THERAPY FOR MOST COMMON EUROPEAN HEPATITIS C VIRUS GENOTYPES", HEPATOLOGY, WILEY, USA, (19981201), vol. 28, no. 6, doi:10.1002/HEP.510280630, ISSN 0270-9139, pages 1674 - 1679, XP008051673 [Y] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1002/hep.510280630
International search[Y]  - TOMEI ET AL., "Characterization of the inhibition of hepatitis C virus RNA replication by nonnuclosides.", J VIROLOGY, (200401), vol. 78, no. 2, pages 938 - 946, XP002407558

DOI:   http://dx.doi.org/10.1128/JVI.78.2.938-946.2004
 [Y]  - GAO ET AL., "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.", NATURE, (20100506), vol. 465, no. 7294, pages 96 - 100, XP008131386

DOI:   http://dx.doi.org/10.1038/nature08960
 [Y]  - FRIDELL ET AL., "Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System.", ANFIMICROB AGENTS CHEMOTHER, (201009), vol. 54, no. 9, pages 3641 - 3650, XP055073884

DOI:   http://dx.doi.org/10.1128/AAC.00556-10
 [Y]  - LEMM ET AL., "identification of hepatitis C virus NS5A inhibitors.", J VIROL, (201001), vol. 84, pages 482 - 491, XP002639563

DOI:   http://dx.doi.org/10.1128/JVI.01360-09
 [A]  - LOVE ET AL., "Crystal structure of a novel dimericform of NS5A domain I protein from hepatitis C virus.", J VIROL, (200905), vol. 83, no. 9, pages 4395 - 4403, XP008162274

DOI:   http://dx.doi.org/10.1128/JVI.02352-08
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.